EGFR anticorps (pTyr845)

N° du produit ABIN967602

Détail du produit anti-EGFR anticorps

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Épitope: pTyr845

Reactivité: Humain, Souris, Rat

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp EGFR est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Marque: BD Pharmingen™

Réactivité croisée: Souris, Rat (Rattus)

Attributs du produit: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
3. Please refer to us for technical protocols.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Phosphorylated Human EGF Receptor Peptide

Clone: 12A3

Isotype: IgG1 kappa

Information d'application

Commentaires:

Related Products: ABIN967389

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store undiluted at 4°C.

Références pour anticorps anti-EGFR (ABIN967602)

Hristozova, Konschak, Budach, Tinhofer: "A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers." dans: Cytometry. Part A : the journal of the International Society for Analytical Cytology, Vol. 81, Issue 6, pp. 489-95, (2012) (PubMed).

Boerner, Demory, Silva, Parsons: "Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II." dans: Molecular and cellular biology, Vol. 24, Issue 16, pp. 7059-71, (2004) (PubMed).

Mendelsohn, Baselga: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." dans: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 21, Issue 14, pp. 2787-99, (2003) (PubMed).

Moro, Dolce, Cabodi, Bergatto, Boeri Erba, Smeriglio, Turco, Retta, Giuffrida, Venturino, Godovac-Zimmermann, Conti, Schaefer, Beguinot, Tacchetti, Gaggini, Silengo, Tarone, Defilippi: "Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines." dans: The Journal of biological chemistry, Vol. 277, Issue 11, pp. 9405-14, (2002) (PubMed).

Wu, Graves, Gill, Parsons, Samet: "Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation." dans: The Journal of biological chemistry, Vol. 277, Issue 27, pp. 24252-7, (2002) (PubMed).

Olayioye, Neve, Lane, Hynes: "The ErbB signaling network: receptor heterodimerization in development and cancer." dans: The EMBO journal, Vol. 19, Issue 13, pp. 3159-67, (2000) (PubMed).

Biscardi, Maa, Tice, Cox, Leu, Parsons: "c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function." dans: The Journal of biological chemistry, Vol. 274, Issue 12, pp. 8335-43, (1999) (PubMed).

Détails sur EGFR

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Autre désignation: EGF Receptor (EGFR Produits)

Synonymes: anticorps C-erb, anticorps CG10079, anticorps D-EGFR, anticorps D-Egf, anticorps DEGFR, anticorps DER, anticorps DER flb, anticorps DER/EGFR, anticorps DER/faint little ball, anticorps DER/top, anticorps DER/torpedo, anticorps DER1, anticorps DEgfr, anticorps Degfr, anticorps Der, anticorps DmHD-33, anticorps Dmel\\CG10079, anticorps EFG-R, anticorps EGF-R, anticorps EGFR, anticorps EGFr, anticorps EGfr, anticorps EK2-6, anticorps Egf, anticorps Egf-r, anticorps EgfR, anticorps El, anticorps Elp, anticorps Elp-1, anticorps Elp-B1, anticorps Elp-B1RB1, anticorps HD-33, anticorps TOP, anticorps Torpedo/DER, anticorps Torpedo/Egfr, anticorps c-erbB, anticorps d-egf-r, anticorps dEGFR, anticorps dEGFR1, anticorps dEgfr, anticorps der, anticorps egfr, anticorps flb, anticorps l(2)05351, anticorps l(2)09261, anticorps l(2)57DEFa, anticorps l(2)57EFa, anticorps l(2)57Ea, anticorps mor1, anticorps top, anticorps top/DER, anticorps top/flb, anticorps torpedo/Egfr, anticorps torpedo/egfr, anticorps EGFR12, anticorps EGFR15, anticorps egfr1, anticorps Erbb2, anticorps ERBB, anticorps ERBB1, anticorps HER1, anticorps PIG61, anticorps mENA, anticorps ErbB-1, anticorps Errp, anticorps 9030024J15Rik, anticorps AI552599, anticorps Erbb, anticorps Errb1, anticorps Wa5, anticorps wa-2, anticorps wa2, anticorps epidermal growth factor receptor, anticorps Epidermal growth factor receptor, anticorps epidermal growth factor receptor a (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian), anticorps EGFR, anticorps Egfr, anticorps egfra, anticorps egfr1, anticorps LOC5564544

Sujet: Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. In addition, c-Src-dependent phosphorylations at other sites, such as tyrosine 845 (Y845) in the kinase domain, regulate the receptor's kinase activity. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies.
The 12A3 monoclonal antibody recognizes the phosphorylated Y845 in the protein tyrosine kinase domain of human EGFR.

Poids moléculaire: 175 kDa

Pathways: Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins